19-Oct-2026 08:31:48
ROSSARI BIOTECH Q2 FY27 ; RECORD QUARTERLY REVENUE, STRONG GROWTH & DEBT REDUCTION 🟢
• Revenue UP 19% YoY to ₹698 crore, driven by domestic growth and international expansion. • H1 FY27 revenue UP 23% YoY to ₹1,395 crore. • HPPC business grew 18% YoY, Textile Specialty Chemicals grew 26% YoY and Animal Health & Nutrition grew 11% YoY. • Gross margin maintained at approximately 32%, while EBITDA margin stood at approximately 12.5%. • Net debt reduced to ₹221 crore from ₹281 crore, a reduction of ₹60 crore. • Working capital cycle improved to 86 days from 97 days in March 2026. • Board approved land leasing for a greenfield manufacturing facility in Saudi Arabia through its wholly owned subsidiary. • Management expects operating leverage, scale benefits, improved product mix and monetisation of non-core assets to support gradual profitability improvement.
ROSSARI BIOTECH LIMITED